SpaceMD Expansion is advancing its space-based pharmaceutical research efforts by adding two experienced industry leaders to its strategic advisory team. Redwire Corporation announced that Paul Reichert and Niki Werkheiser will support SpaceMD’s future growth in biotechnology and medicine development.
Reichert previously worked with Merck Research Laboratories, where he contributed to pharmaceutical research and drug development programs. Meanwhile, Werkheiser brings extensive experience from NASA’s space technology initiatives and commercial space partnerships.
Together, the new advisors will help SpaceMD improve its research strategy and expand its pharmaceutical opportunities. Additionally, they will support collaborations with biotechnology companies and develop new approaches for creating medicines in microgravity environments.
Reichert will serve as a scientific advisor for SpaceMD. In this role, he will help identify promising drug candidates and guide the company’s orbital research and manufacturing plans.
Furthermore, Reichert’s previous pharmaceutical experience includes work involving molecular research and drug formulation. During his career at Merck and Schering-Plough, he contributed to studies that improved understanding of complex pharmaceutical development processes.
Werkheiser will join SpaceMD as a strategic advisor. She will focus on expanding partnerships and exploring new opportunities for space-based pharmaceutical research.
Previously, Werkheiser served as NASA’s director of technology maturation. During that time, she managed significant technology investments involving government and industry partners.
Additionally, she helped establish NASA’s In-Space Manufacturing Initiative. The program focused on developing new capabilities for future space missions and long-term exploration efforts.
SpaceMD uses microgravity conditions in space to support pharmaceutical innovation. The company operates its Pharmaceutical In-Space Laboratory technology to grow specialized crystals for medical research.
These space-grown crystals can help companies improve existing medicines or develop new treatments. As a result, researchers can study pharmaceutical materials under conditions that are difficult to recreate on Earth.
Since its first laboratory launch in 2023, SpaceMD has sent dozens of research systems to the International Space Station. These missions have successfully processed numerous compounds, including important molecules connected to major health conditions.
Moreover, SpaceMD continues working with pharmaceutical partners to explore new medical applications. The company believes space-based research can create valuable opportunities for future drug development.
The addition of Reichert and Werkheiser supports the company’s goal of expanding its capabilities. Their combined experience covers pharmaceutical science, space technology, commercialization, and large-scale research programs.
SpaceMD Expansion reflects the growing interest in using space environments for healthcare innovation. As the commercial space industry develops, companies are exploring new ways to use microgravity for scientific discoveries.
Redwire Corporation continues supporting advanced aerospace and defense technology solutions through its various operations. The company focuses on developing new platforms and systems for future space and technology markets.
Overall, SpaceMD Expansion highlights a growing connection between space exploration and pharmaceutical research. With new advisors and advanced laboratory technology, SpaceMD aims to accelerate medical discoveries through space-based innovation.
